SIX WEEKS OF DAILY RIFAPENTINE VS. A COMPARATOR ARM OF 12-16 WEEK RIFAMYCIN-BASED TREATMENT OF LATENT M. TUBERCULOSIS INFECTION: ASSESSMENT OF SAFETY, TOLERABILITY AND EFFECTIVENESS

Registry ID

TBTC STUDY 37 - 7024

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE

Start date

2024-04-11

Last update

2021-08-10

Conditions

• LATENT TUBERCULOSIS (TB) INFECTION

Related clinical trials

• STUDY 38 - PHASE 2C CLINICAL TRIAL OF NOVEL, SHORT-COURSE REGIMENS FOR THE TREATMENT OF PULMONARY TUBERCULOSIS: CRUSH-TB (COMBINATION REGIMENS FOR SHORTENING TB TREATMENT)
• SSTARLET: SHORTER AND SAFER TREATMENT REGIMENS FOR LATENT TB
• 2R2: HIGHER DOSE RIFAMPIN FOR 2 MONTHS VS STANDARD DOSE RIFAMPIN FOR LATENT TB:A 3-ARM RANDOMIZED TRIAL

View on source registry